entertainment -WSS

entertainment

author：Wikipedia 2025-08-26 23:48:55 - browse：13

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： The history of OxyContin, told through Purdue Pharma documents

focus

WSS

What we owe ALS patients — and why one company fell short

With Roe v Wade overturned, abortion providers work to adapt

CDC overhauls leadership of center that led response to Covid

The Karikó problem: Lessons for funding basic research

Flu, Covid vaccination rates decline, new survey data show

Maui funeral service workers on devastation of fires: 'I'm in shock'

leisure time

entertainment

leisure time

The high cost of giving birth even with insurance

Pharma budget tightening trickles down to Doximity

The cancer drug shortage isn’t new — and neither are the solutions

Lawsuit highlights wrinkle for disputes over surprise medical bills

DIEP, the 'gold standard' of breast reconstruction, is under threat

CDC picks Alphabet's Verily for wasterwater surveillance contract

Alkermes shareholders re

With Roe v Wade overturned, abortion providers work to adapt

Walensky prepares to leave CDC — and Congress — behind

Lawsuit highlights wrinkle for disputes over surprise medical bills

entertainment

6 solutions to address cancer drug shortages and others

The biotech scorecard for Q4: 16 stock

Target recalls 2.2 million additional candles due to laceration, burn hazards

An innovative path out of biotech’s “valley of death”

Experts study whether long Covid risk adds up with each reinfection

Faced with fears of OxyContin misuse, sales reps touted its safety

explore

focus

leisure time

hotspot